19,782 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,782 shares of the company’s stock, valued at approximately $403,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Denali Therapeutics by 33.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,757 shares of the company’s stock worth $810,000 after purchasing an additional 10,038 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Denali Therapeutics by 177.1% in the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after purchasing an additional 4,449 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after acquiring an additional 885 shares in the last quarter. E Fund Management Co. Ltd. increased its position in shares of Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after acquiring an additional 2,436 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Denali Therapeutics in the fourth quarter worth approximately $533,000. 92.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DNLI has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. B. Riley reissued a “buy” rating and issued a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 target price on the stock. Finally, Bank of America dropped their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $37.20.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares in the company, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the transaction, the director now owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by insiders.

Denali Therapeutics Stock Up 1.7 %

NASDAQ DNLI opened at $15.15 on Monday. The stock has a market capitalization of $2.20 billion, a PE ratio of -5.49 and a beta of 1.46. The company has a 50 day moving average price of $20.26 and a two-hundred day moving average price of $23.96. Denali Therapeutics Inc. has a 12-month low of $14.01 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.